Atezolizumab for the First-Line Treatment of Non-small Cell Lung Cancer (NSCLC): Current Status and Future Prospects

Purpose: Atezolizumab is a programmed death ligand 1 (PDL-1) blocking antibody that was approved for metastatic non-small cell lung cancer (NSCLC) in patients with disease progression. Various studies have been initiated to explore the effectiveness of atezolizumab among different patient cohorts an...

Descripción completa

Detalles Bibliográficos
Autores principales: Ryu, Rachel, Ward, Kristina E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6066722/
https://www.ncbi.nlm.nih.gov/pubmed/30087855
http://dx.doi.org/10.3389/fonc.2018.00277

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6066722/
https://www.ncbi.nlm.nih.gov/pubmed/30087855
http://dx.doi.org/10.3389/fonc.2018.00277

Ejemplares similares